Clinical Trial Update: Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) [Phase 3]

View source ↗

Summary

Phase 3 SUMIT trial evaluating selumetinib (AZD6244) in metastatic uveal melanoma has completed, with results posted on 2016-09-28.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic, Uveal Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2016-09-28